Arvinas (NASDAQ:ARVN) Stock Price Up 8.7% - Still a Buy?

Arvinas, Inc. (NASDAQ:ARVN - Get Free Report) shares rose 8.7% on Friday . The company traded as high as $7.52 and last traded at $7.52. Approximately 1,421,506 shares traded hands during trading, an increase of 3% from the average daily volume of 1,386,359 shares. The stock had previously closed at $6.92.

Analyst Upgrades and Downgrades

ARVN has been the topic of several analyst reports. Oppenheimer lowered shares of Arvinas from an "outperform" rating to a "market perform" rating in a report on Tuesday, March 11th. BMO Capital Markets dropped their price target on shares of Arvinas from $20.00 to $10.00 and set an "outperform" rating for the company in a research report on Monday, May 5th. Truist Financial reaffirmed a "hold" rating and set a $11.00 price objective (down from $21.00) on shares of Arvinas in a report on Monday, May 5th. Bank of America dropped their target price on Arvinas from $54.00 to $28.00 and set a "buy" rating for the company in a report on Wednesday, March 12th. Finally, UBS Group cut their target price on Arvinas from $74.00 to $21.00 and set a "buy" rating for the company in a research report on Thursday, May 15th. Ten analysts have rated the stock with a hold rating and twelve have issued a buy rating to the stock. According to MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $20.29.

Arvinas Trading Up 8.2%

The stock has a market cap of $546.70 million, a price-to-earnings ratio of -2.68 and a beta of 2.21. The firm has a fifty day simple moving average of $7.27 and a 200-day simple moving average of $14.24.

Arvinas (NASDAQ:ARVN - Get Free Report) last issued its quarterly earnings results on Thursday, May 1st. The company reported $1.14 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.93) by $2.07. Arvinas had a negative return on equity of 33.75% and a negative net margin of 75.51%. The firm's revenue was up 646.2% on a year-over-year basis. During the same quarter last year, the firm earned ($0.97) EPS. On average, equities analysts predict that Arvinas, Inc. will post -3.81 earnings per share for the current fiscal year.

Insider Activity

In related news, insider Noah Berkowitz sold 8,658 shares of the business's stock in a transaction that occurred on Tuesday, March 18th. The shares were sold at an average price of $8.59, for a total transaction of $74,372.22. Following the completion of the transaction, the insider now owns 110,023 shares in the company, valued at approximately $945,097.57. The trade was a 7.30% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 4.73% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of the stock. Rhumbline Advisers raised its stake in shares of Arvinas by 3.8% in the 1st quarter. Rhumbline Advisers now owns 91,210 shares of the company's stock valued at $640,000 after purchasing an additional 3,333 shares during the period. Acadian Asset Management LLC bought a new stake in Arvinas in the 1st quarter valued at approximately $1,123,000. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its position in Arvinas by 108.3% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 902,925 shares of the company's stock worth $6,339,000 after acquiring an additional 469,394 shares during the last quarter. Woodline Partners LP grew its stake in shares of Arvinas by 0.5% during the 1st quarter. Woodline Partners LP now owns 695,945 shares of the company's stock worth $4,886,000 after acquiring an additional 3,212 shares in the last quarter. Finally, Philosophy Capital Management LLC acquired a new stake in shares of Arvinas in the first quarter valued at approximately $6,992,000. Institutional investors own 95.19% of the company's stock.

About Arvinas

Arvinas, Inc, a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.